NASDAQ:MYOS MYOS RENS Technology (MYOS) Stock Price, News & Analysis → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free MYOS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$1.01▼$11.4052-Week Range N/AVolumeN/AAverage Volume1.68 million shsMarket Capitalization$16.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get MYOS RENS Technology alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About MYOS RENS TechnologyMedAvail Holdings, Inc. is a technology-enabled pharmacy company. It provides turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. The firm helps patients to optimize drug adherence, resulting in better health outcomes. The company is headquartered in Mississauga, Canada.Read More Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. MYOS Stock News HeadlinesDecember 23, 2023 | bbc.comRen Zhengfei says US government 'underestimates' HuaweiMay 11, 2023 | marketwatch.comBio-active Peptides Market Size 2023-2031 Industrial Trends by Absolute Reports | with [93 Pages]April 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.May 8, 2023 | marketwatch.comLatest "Bio-active Peptides Market" Size Forecast 2023-2031: New Challenges, Drivers, and RestraintsApril 13, 2023 | marketwatch.comBio-active Peptides Market Size Dynamics 2023-2029March 21, 2023 | marketwatch.comGlobal Bio-active Peptides Market: Future Extrapolations and Emerging Updates for 2023-2027March 13, 2023 | marketwatch.comBio-active Protein Market Size 2023 Research Report by Industrial Growth Analysis and Forecast till 2027September 28, 2022 | marketwatch.comBio-active Peptides Market Size, Share, 2022 Global Trends, Development Status, Opportunities, Competitive Landscape and Growth by Forecast 2028April 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.August 4, 2022 | marketwatch.comBio-Active Protein Market Is Likely to Experience a Strong Growth During 2022-2028 with Top Countries DataSeptember 26, 2021 | yahoo.comICYMI: Everything you need to know about the iPhone 13July 29, 2021 | nasdaq.comMYOS RENS Technology Inc. Common Stock (MYOS)See More Headlines Receive MYOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MYOS RENS Technology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2019Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:MYOS CUSIPN/A CIK1402479 Webwww.myosrens.com Phone(905) 812-0023FaxN/AEmployees15Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,260,000.00 Net Margins-277.82% Pretax MarginN/A Return on Equity-166.68% Return on Assets-104.95% Debt Debt-to-Equity Ratio0.11 Current Ratio3.78 Quick Ratio1.94 Sales & Book Value Annual Sales$1.03 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / BookN/AMiscellaneous Outstanding Shares12,192,000Free FloatN/AMarket Cap$16.70 million OptionableNot Optionable Beta1.08 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesEd KilroyPresident, Chief Executive Officer & DirectorRyan FergusonChief Financial Officer, Secretary & TreasurerFraser MackayChief Information OfficerDavid John RawlinsChief Commercial OfficerNeil PreziosoChief Pharmacy OfficerKey CompetitorsVBI VaccinesNASDAQ:VBIVTalpheraNASDAQ:TLPHCocrystal PharmaNASDAQ:COCPMinerva NeurosciencesNASDAQ:NERVBenitec BiopharmaNASDAQ:BNTCView All Competitors MYOS Stock Analysis - Frequently Asked Questions How were MYOS RENS Technology's earnings last quarter? MYOS RENS Technology Inc. (NASDAQ:MYOS) posted its earnings results on Tuesday, August, 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.01. The business earned $0.15 million during the quarter, compared to analyst estimates of $0.14 million. MYOS RENS Technology had a negative net margin of 277.82% and a negative trailing twelve-month return on equity of 166.68%. What other stocks do shareholders of MYOS RENS Technology own? Based on aggregate information from My MarketBeat watchlists, some companies that other MYOS RENS Technology investors own include Chesapeake Energy (CHKAQ), Catalyst Pharmaceuticals (CPRX), Biocept (BIOC), Global Blood Therapeutics (GBT), Sorrento Therapeutics (SRNE), T2 Biosystems (TTOO), AbbVie (ABBV), AcelRx Pharmaceuticals (ACRX) and BioLineRx (BLRX). This page (NASDAQ:MYOS) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MYOS RENS Technology Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
